Pulmonary Thromboembolism in Immune Thrombocytopenia: A Report of Five Cases and a Review of the Literature

References

• Rodeghiero F. Is ITP a thrombophilic disorder? Am J Hematol. 2016;91(1):39–45. doi:10.1002/ajh.24234
   PubMed Web of Science ®Google Scholar
• Kraaijpoel N, Tritschler T, Guillo E, Girard P, Le Gal G. Definitions, adjudication, and reporting of pulmonary embolism-related death in clinical studies: a systematic review. J Thromb Haemost. 2019;17(10):1590–1607. doi:10.1111/jth.14570
   PubMed Web of Science ®Google Scholar
• Feudjo-Tepie MA, Le Roux G, Beach KJ, Bennett D, Robinson NJ. Comorbidities of idiopathic thrombocytopenic purpura: a population-based study. Adv Hematol. 2009;2009:963506. doi:10.1155/2009/963506
   PubMedGoogle Scholar
• Feudjo-Tepie MA, Hall SA, Logie J, Robinson NJ. Risk of cataract among idiopathic thrombocytopenic purpura patients in the UK general practice research database. Pharmacoepidemiol Drug Saf. 2009;18(5):380–385. doi:10.1002/pds.1723
   PubMed Web of Science ®Google Scholar
• Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J; ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004;76(3):205–213. doi:10.1002/ajh.20104
   PubMed Web of Science ®Google Scholar
• Bennett D, Forssen U, Enger C, et al. Risk of thromboembolic events(TE) among patients with chronic idiopathic thrombocytopenic purpura (ITP). Haematologica. 2008;93(Supplement1):125.
   Google Scholar
• Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–2634. doi:10.1182/blood-2004-03-1168
   PubMed Web of Science ®Google Scholar
• Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol. 2003;50(3):172–175. doi:10.1159/000073059
   PubMed Web of Science ®Google Scholar
• Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010;107(9):1047–1057. doi:10.1161/CIRCRESAHA.110.226456
   PubMed Web of Science ®Google Scholar
• Owens AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108(10):1284–1297. doi:10.1161/CIRCRESAHA.110.233056
   PubMed Web of Science ®Google Scholar
• Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Żuber Z, Wojtkiewicz M, Wojtkiewicz J. Role of microparticles in the pathogenesis of inflammatory joint diseases. Int J Mol Sci. 2019;20(21):5453. doi:10.3390/ijms20215453
   PubMed Web of Science ®Google Scholar
• Wong RS, Bakshi K, Brainsky A. Thrombophilia in patients with chronic immune thrombocytopenia. Scand J Clin Lab Invest. 2015;75(1):13–17. doi:10.3109/00365513.2014.962597
   PubMed Web of Science ®Google Scholar
• Moulis G, Audemard-Verger A, Arnaud L, et al. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis. Autoimmun Rev. 2016;15(3):203–209. doi:10.1016/j.autrev.2015.11.001
   PubMed Web of Science ®Google Scholar
• Jain A, Saluja S, Chaudhry S, Gupta DK. Recurrent arterial and venous thrombosis in chronic immune thrombocytopenia: clinical paradox and therapeutic challenges. Indian J Hematol Blood Transfus. 2019;35(3):590–592. doi:10.1007/s12288-019-01136-3
   PubMed Web of Science ®Google Scholar
• Najaoui A, Bakchoul T, Stoy J, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88(2):167–174. doi:10.1111/j.1600-0609.2011.01718.x
   PubMed Web of Science ®Google Scholar
• Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16(5):313–318. doi:10.1097/01.mbc.0000172694.85233.a8
   PubMed Web of Science ®Google Scholar
• Alvarado RG, Liu JY, Zwolak RM. Danazol and limb-threatening arterial thrombosis: two case reports. J Vasc Surg. 2001;34(6):1123–1126. doi:10.1067/mva.2001.118078
   PubMed Web of Science ®Google Scholar
• Fontana V, Jy W, Ahn ER, et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res. 2008;122(5):599–603. doi:10.1016/j.thromres.2007.12.022
   PubMed Web of Science ®Google Scholar
• Lippi G, Favaloro EJ, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med. 2010;48(12):1693–1701. doi:10.1515/CCLM.2010.335
   PubMed Web of Science ®Google Scholar
• Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003;1(7):1343–1348. doi:10.1046/j.1538-7836.2003.00261.x
   PubMed Web of Science ®Google Scholar
• Croles FN, Borjas-Howard J, Nasserinejad K, Leebeek FWG, Meijer K. Risk of venous thrombosis in antithrombin deficiency: a systematic review and Bayesian meta-analysis. Semin Thromb Hemost. 2018;44(4):315–326. doi:10.1055/s-0038-1625983
   PubMed Web of Science ®Google Scholar
• Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: a narrative review with emphasis on primary systemic vasculitides. Vasc Med. 2015;20(4):369–376. doi:10.1177/1358863X15573838
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348–358. doi:10.1055/s-0034-1370794
   PubMed Web of Science ®Google Scholar
• Kopolovic I, Lee AY, Wu C. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol. 2015;94(2):329–336. doi:10.1007/s00277-014-2198-6
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488. doi:10.1182/blood-2002-01-0108
   PubMed Web of Science ®Google Scholar
• Labrador J, Lopez-Anglada L, Perez-Lopez E, et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica. 2013;98(3):437–443. doi:10.3324/haematol.2012.069559
   PubMed Web of Science ®Google Scholar
• Houghton DE, Key NS, Zakai NA, Laux JP, Shea TC, Moll S. Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. Leuk Lymphoma. 2017;58(11):2573–2581. doi:10.1080/10428194.2017.1306644
   PubMed Web of Science ®Google Scholar